T1 Organism 5 13 patients
T2 Protein 569 572 RNA
T3 Intervention 449 457 Biopsies
T4 Organism 420 428 patients
T5 Condition 1199 1225 aggressive multisystem LCH
T6 Protein 757 795 extracellular signalâ€“regulated kinase 
T7 Condition 88 111 Erdheim-Chester disease
T8 Gene 529 536 genomic
T9 Protein 898 904 MAP2K1
T10 Protein 113 116 ECD
T11 Organism 1185 1193 patients
T12 Gene 992 1009 in-frame deletion
T13 Organism 593 601 patients
T14 Protein 561 564 DNA
T15 Protein 800 877  and were sensitive to inhibitors of mitogen-activated protein kinase kinase 
T16 Disease 19 40 histiocytic disorders
T17 Condition 80 83 LCH
T18 Protein 1112 1137 V600E-specific inhibitors
T19 Protein 1088 1093  ERK 
T20 Condition 374 383 mutations
T21 Organism 464 472 patients
T22 Intervention 123 151 treatment-refractory disease
T23 Condition 49 78 Langerhans cell histiocytosis
T24 Gene 626 645 BRAF V600E mutation
T25 Gene 1013 1017 BRAF
T27 Condition 1222 1225 LCH
T28 Organism 966 974 patients
T29 Protein 698 704 MAP2K1
T30 Condition 685 694 mutations
T31 Biomarker 434 447 histiocytoses
T32 Biomarker 491 504 histiocytoses
T33 Gene 936 954 ALK rearrangements
T35 Condition 962 965 LCH
T36 Biomarker 212 225 histiocytoses
T37 Gene 1380 1387 genomic
T38 Gene 344 349 genes
T39 Organism 654 662 patients
T40 Protein 1089 1092 ERK
T41 Condition 194 208 gene mutations
T42 Gene 626 630 BRAF
